Advanced

Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations

Ahlqvist-Rastad, Jane; Albertsson, Maria; Bergh, Jonas; Birgegard, Gunnar; Johansson, Peter; Jonsson, Bertil; Kjellén, Elisabeth LU ; Pahlman, Sven; Zackrisson, Bjorn and Osterborg, Anders (2007) In Medical Oncology 24(3). p.267-272
Abstract
Due to concerns related to treatment with erythropoietin (EPO) and possible negative effects on tumour control, a workshop was organised by the Medical Products Agency of Sweden with the aim to revise national treatment guidelines if needed. In patients with solid tumours, conflicting results have been reported with respect to tumour control and survival. Until further notice it is therefore recommended that EPO should be used restrictively in the treatment of patients with cancer and that the anticipated improvement in quality of life should be evaluated against potential risks.
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
erythropoietin, safety, cancer therapy, epoetin, anemia, receptor
in
Medical Oncology
volume
24
issue
3
pages
267 - 272
publisher
Humana Press
external identifiers
  • wos:000249339900001
  • scopus:36248997063
ISSN
1559-131X
DOI
10.1007/s12032-007-0037-5
language
English
LU publication?
yes
id
1f09295c-bded-48ca-9f6c-9d9bbbeaa107 (old id 657078)
alternative location
http://humanapress.com/index.php?option=com_journalshome&task=articledetails&category=journals&article_code=MO:24:3:267
date added to LUP
2007-12-11 12:50:45
date last changed
2017-01-01 07:07:40
@article{1f09295c-bded-48ca-9f6c-9d9bbbeaa107,
  abstract     = {Due to concerns related to treatment with erythropoietin (EPO) and possible negative effects on tumour control, a workshop was organised by the Medical Products Agency of Sweden with the aim to revise national treatment guidelines if needed. In patients with solid tumours, conflicting results have been reported with respect to tumour control and survival. Until further notice it is therefore recommended that EPO should be used restrictively in the treatment of patients with cancer and that the anticipated improvement in quality of life should be evaluated against potential risks.},
  author       = {Ahlqvist-Rastad, Jane and Albertsson, Maria and Bergh, Jonas and Birgegard, Gunnar and Johansson, Peter and Jonsson, Bertil and Kjellén, Elisabeth and Pahlman, Sven and Zackrisson, Bjorn and Osterborg, Anders},
  issn         = {1559-131X},
  keyword      = {erythropoietin,safety,cancer therapy,epoetin,anemia,receptor},
  language     = {eng},
  number       = {3},
  pages        = {267--272},
  publisher    = {Humana Press},
  series       = {Medical Oncology},
  title        = {Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations},
  url          = {http://dx.doi.org/10.1007/s12032-007-0037-5},
  volume       = {24},
  year         = {2007},
}